An increased abundance of eicosapentaenoic acid is associated with a reduced risk of heart failure, and this protective effect is independent of established risk factors and ejection fraction status, according to a study presented at the 2018 American Heart Association (AHA) Scientific Sessions in Chicago, Illinois, US.
The use of low-dose intracoronary alteplase, a tissue plasminogen activator (tPA), in patients with acute ST-elevation myocardial infarction (STEMI) at the time of primary percutaneous coronary intervention (PCI) was ineffective in reducing microvascular obstruction (MVO, or failed myocardial reperfusion), according to the T-TIME* trial results presented at AHA 2018.
Treatment with the SGLT2i* empagliflozin appears to significantly reduce left ventricular mass (LVM) among patients with type 2 diabetes (T2D), according to results of the EMPA-HEART** CardioLink-6 trial presented at AHA 2018.
Coronary revascularization with bypass surgery proves to be superior to drug eluting stents in the long term in preventing all-cause mortality in patients with diabetes mellitus (DM) and multivessel coronary disease (MVD), even 8 years after the procedure, the FREEDOM* Follow-On Study reveals.
Dapagliflozin reduced the risk of hospitalization for heart failure (HHF) in patients with type 2 diabetes (T2D) who had established or multiple risk factors for atherosclerotic cardiovascular disease (CVD), according to results of the DECLARE-TIMI 58* trial presented at AHA 2018. However, it did not reduce the incidence of major adverse cardiovascular events (MACE)**.
Lipid-lowering with ezetimibe monotherapy was effective for the primary prevention of atherosclerotic cardiovascular (CV) events in middle- to high-risk elderly Japanese patients with hypercholesterolaemia, according to the EWTOPIA75* study presented at AHA 2018 Scientific Sessions.
Supplementation with either omega-3 fatty acids (ie, fish oil) or vitamin D did not reduce the incidence of major cardiovascular (CV) events (ie, composite of myocardial infarction [MI], stroke, and CV death) or total invasive cancer, according to the VITAL* trial presented at AHA 2018.
The administration of sacubitril-valsartan, an angiotensin receptor-neprilysin inhibitor, during hospitalization significantly reduces the N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels among patients with acute decompensated heart failure (ADHF) and reduced ejection fraction compared with enalapril, according to the PIONEER-HF* trial presented at AHA 2018 Scientific Sessions.
Low-dose methotrexate, which is approved for the treatment of rheumatoid arthritis (RA) and other autoimmune disorders, has shown unexpectedly disappointing results in preventing cardiovascular (CV) events among patients with a prior myocardial infarction (MI) or multivessel coronary disease, according to CIRT*, potentially ruling out what could be an affordable option for treating inflammation related to atherosclerosis.
The risk of cardiovascular (CV) disease (CVD) is significantly higher among patients with rheumatoid arthritis (RA) than those with type 2 diabetes (T2D), results of the CARRÉ* study reveal. Such risk persisted even after adjusting for traditional CV risk factors, which suggests that systemic inflammation is an independent contributor to CV risk.
A recent retrospective study from Singapore identified several factors associated with a higher risk of mortality following hip fracture, including male sex, older age, and a higher number of comorbidities.